Key result
In patients with hemodynamically stable acute heart failure, ivabradine exposure was associated with a lower risk of all-cause mortality and HF rehospitalization (HR 0.51; 95% CI 0.28-0.91; p<.05).
Why the study?
Initiating ivabradine in acute heart failure remains controversial, leading to the hypothesis that it may be effective when added in acute but hemodynamically stable HF.
Does ivabradine reduce all-cause mortality and HF rehospitalization in patients with acute but hemodynamically stable heart failure?
Cohort (n=126)
Does ivabradine reduce all-cause mortality and HF rehospitalization in patients with acute but hemodynamically stable heart failure?
Hazard Ratio: 0.51 (95% CI 0.28–0.91)
p-value: p=<.05
Initiating ivabradine in acute but hemodynamically stable heart failure may significantly reduce heart rate, improve cardiac function, and reduce HF rehospitalization.
May support ivabradine in acute stable HF; leaves open confirmation by randomized trials.
BACKGROUND: Initiating ivabradine in acute heart failure (HF) is still controversial. HYPOTHESIS: Ivabradine might be effective to be added in acute but hemodynamically stable HF. METHODS: A retrospective cohort of hemodynamically stable acute HF patients was enrolled from January 2018 to January 2020 and followed until July 2020. The primary endpoints were all-cause mortality and rehospitalization for HF. Secondary endpoints included heart rate (HR), cardiac function measured by New York Heart Association (NYHA) class, and left ventricular ejection fraction (LVEF) and adverse events, which were compared between patients with or without ivabradine. RESULTS: A total of 126 patients were enrolled (50 males, median age 54 years, 81% with decompensated HF, median follow-up of 9 months). In patients treated with ivabradine, although baseline HRs were higher than the reference group (96 vs. 80 bpm), they were comparable after 3 months; more patients tolerated high doses of β-blockers (27% vs. 7.9%), improved to NYHA class I function (55.6% vs. 23.8%) and exhibited normal LVEFs (37.8% vs. 14.3%) than the reference group (all p < .05). Ivabradine was associated with a significant reduction of rehospitalization for HF than the reference group (25.4% vs.61.9%), with longer event-free survival times (hazard ratio: 0.45, 95% confidence interval [CI]: 0.25-0.79), and was related with primary endpoints negatively (hazard ratio 0.51, 95% CI: 0.28-0.91) (all p < .05). CONCLUSION: In patients with acute but hemodynamically stable HF, ivabradine may significantly reduce HR, improve cardiac function, and reduce HF rehospitalization.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2022) conducted a cohort in Hemodynamically stable acute heart failure (n=126). Ivabradine vs. Patients without ivabradine was evaluated on All-cause mortality and rehospitalization for HF (HR 0.51, 95% CI 0.28-0.91, p=<.05). In patients with hemodynamically stable acute heart failure, ivabradine exposure was associated with a lower risk of all-cause mortality and HF rehospitalization (HR 0.51; 95% CI 0.28-0.91; p<.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: